US · Healthcare · Biotechnology
EPS came in at 0.25 against a street estimate of 0.08 — a beat of 212.5%.
Analysts rate Zevra Therapeutics Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $25.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.50% |
| Woodline Partners LP | 5.81% |
| FMR Inc | 5.41% |
| Nantahala Capital Management, LLC | 4.25% |
| Vanguard Capital Management, LLC | 4.16% |
| State Street Corp | 2.63% |
| Geode Capital Management, LLC | 2.31% |
| D. E. Shaw & Co LP | 2.20% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ZEVRA THERAPEUTICS, INC. — Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & investments (combined): $260.2 million as of June 30, 2026 ($145.3M c | 2026-08-05 |
| Results announced · Q3 2026 ZEVRA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net revenue: $39.7 million (up 53% vs. Q2 2025's $25.9 million) • MIPLYFFA r | 2026-08-05 |
| Shareholder vote results · Q2 2026 ZEVRA THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Shareholder Voting Participation: 46,326,616 shares voted out of 59,114,850 outstandi | 2026-06-05 |
| Quarterly report · Q1 2026 ZEVRA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q1 2026): $36.2 million vs. $20.4 million (Q1 2025) – 78% increase • Net | 2026-05-06 |
| Results announced · Q2 2026 ZEVRA THERAPEUTICS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 net revenue: $36.2 million (78% increase vs. Q1 2025's $20.4 million) • Net | 2026-05-06 |
| Proxy statement · Q2 2026 ZEVRA THERAPEUTICS, INC. – 2026 PROXY SUMMARY CEO COMPENSATION & CHANGE • Neil F. McFarlane (President and CEO) total compensation: Not explicitly s | 2026-04-20 |
| Material agreement · Q1 2026 ZEVRA THERAPEUTICS, INC. - FORM 8-K SUMMARY Filing Date: March 16, 2026 --- HEADLINE NUMBERS • $50.0 million in total cash to be received from Comm | 2026-03-16 |
| Annual report FY2025 ZEVRA THERAPEUTICS, INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company is a commercial-stage rare disease pharmaceutical firm with | 2026-03-09 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zevra Therapeutics Inc. — free to start.
Google PlayApp StoreData updated 2026-09-18.